Median Technologies Forms Strategic Review Committee to Unlock Value Amid Undervaluation — Median Technologies SA

Event summary

Median Technologies' Board formed a Strategic Review Committee (SRC) to explore alternatives to enhance shareholder value, including potential separation of its iCRO and eyonis® businesses.
The company also established an R&D Committee to oversee scientific and technical development of the eyonis® pan-cancer platform.
Median raised €50 million in June 2026, extending its cash runway through H1 2028, with additional potential cash inflow from warrant exercises.
The SRC will evaluate potential U.S. listing for eyonis® or combined businesses to broaden shareholder base and improve access to capital markets.
eyonis® LCS received FDA 510(k) clearance in February 2026 and CE Mark in July 2026, with a strategic partnership with Tempus AI for distribution.

The big picture

Median Technologies' strategic review comes amid a series of transformational milestones, including FDA and CE Mark approvals for eyonis® LCS and a €50 million capital raise. The Board believes the current public market valuation does not reflect the intrinsic value and growth potential of eyonis® and iCRO. The formation of the SRC and R&D Committee signals a shift towards unlocking value through structural alternatives and disciplined scientific expansion, aligning with broader industry trends in AI-powered medical devices and oncology diagnostics.

What we're watching

Structural Separation: Whether the potential separation of iCRO and eyonis® businesses will unlock distinct valuations and growth trajectories.
U.S. Market Access: The pace at which a potential U.S. listing for eyonis® or combined businesses could broaden the shareholder base and improve capital access.
Pan-Cancer Expansion: How the R&D Committee's oversight will accelerate the scientific and technical development of the eyonis® platform beyond lung cancer screening.